Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

BSB 1001

Next Previous
X
Search
Drug Profile

BSB 1001

Alternative Names: BSB-1001; miHA 1 targeting TCR T cell therapy - BlueSphere Bio

Latest Information Update: 18 Jun 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator BlueSphere Bio
  • Class Antineoplastics; Gene therapies; Immunotherapies; T lymphocyte cell therapies
  • Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Leukaemia

Most Recent Events

  • 03 Jun 2024 BlueSphere Bio plans phase-I/IIa TCX-101 trial for Leukemia (Second-line therapy or greater, Combination therapy) in 4Q2024 (Parenteral)
  • 03 Jun 2024 US FDA approves IND application for a phase-I/IIa TCX-101 trial for BSB 1001 for Leukemia (Second-line therapy or greater)
  • 30 May 2024 BlueSphere Bio plans a phase I/Ib trial for Acute myeloid leukaemia, Precursor cell lymphoblastic leukaemia-lymphoma and Myeloidysplastic syndromes and anticipates dosing its first patient in early 2025

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top